Amylin Pharmaceuticals to Webcast Year-End Results

SAN DIEGO, Jan. 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the
fourth quarter and full year 2007 on Monday, January 28, 2008 at 5:00 p.m.
ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's President and Chief Executive
Officer, will lead the call. On the same date post market, Amylin will release
financial results for the fourth quarter and year ended December 31, 2007.
The call will be webcast live through Amylin's corporate website and a
recording will be made available following the close of the call. To access
the webcast, please log on to http://www.amylin.com approximately fifteen
minutes prior to the call to register, download and install any necessary
audio software. For those without access to the Internet, the live call may be
accessed by phone by calling (800) 901-5231 (domestic) or (617) 786-2961
(international), passcode 53471601. A replay of the call will also be
available by phone for 24 hours beginning approximately one hour after the
close of the call and can be accessed at (888) 286-8010 (domestic) or
(617) 801-6888 (international), passcode 32667415.
About Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two first-
in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and
BYETTA(R) (exenatide) injection. Amylin's research and development activities
leverage the company's expertise in metabolism to develop potential therapies
to treat diabetes and obesity. Amylin is located in San Diego, California with
over 1,900 employees nationwide. Further information on Amylin Pharmaceuticals
is available at http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.

Michael York, Senior Director, Investor Relations of Amylin Pharmaceuticals,
Inc., +1-858-552-2200, ext. 8602